{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:14:44Z","timestamp":1740147284620,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13256-019-2075-y","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:03:27Z","timestamp":1557878607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report"],"prefix":"10.1186","volume":"13","author":[{"given":"Juan C.","family":"Falla-Martinez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Baena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa X.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz F.","family":"Sua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0846-8129","authenticated-orcid":false,"given":"Angela R.","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"issue":"2","key":"2075_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3322\/caac.20102","volume":"61","author":"SS Ramalingam","year":"2011","unstructured":"Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61(2):91\u2013112. \n                    https:\/\/doi.org\/10.3322\/caac.20102\n                    \n                  .","journal-title":"CA Cancer J Clin"},{"key":"2075_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.lungcan.2017.04.016","volume":"109","author":"GM O\u2019Kane","year":"2017","unstructured":"O\u2019Kane GM, Bradbury PA, Feld R, et al. Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer. 2017;109:137\u201344. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2017.04.016\n                    \n                  .","journal-title":"Lung Cancer"},{"issue":"2","key":"2075_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154\u201362. \n                    https:\/\/doi.org\/10.1097\/JTO.0000000000000033\n                    \n                  .","journal-title":"J Thorac Oncol"},{"issue":"10","key":"2075_CR4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa0904554","volume":"361","author":"R Rosell","year":"2009","unstructured":"Rosell R, Moran T, Queralt C, et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. N Engl J Med. 2009;361(10):958\u201367. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0904554\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"1","key":"2075_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/JTO.0b013e3182781e35","volume":"8","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi S, Canepa HM, Bailey AS, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(1):118\u201322. \n                    https:\/\/doi.org\/10.1097\/JTO.0b013e3182781e35\n                    \n                  .","journal-title":"J Thorac Oncol"},{"key":"2075_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.lungcan.2016.01.019","volume":"94","author":"LY Chen","year":"2016","unstructured":"Chen LY, Molina-Vila MA, Ruan SY, et al. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 2016;94:46\u201353. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2016.01.019\n                    \n                  .","journal-title":"Lung Cancer"},{"issue":"9","key":"2075_CR7","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","volume":"24","author":"S Dearden","year":"2013","unstructured":"Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24(9):2371\u20136. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdt205\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"5","key":"2075_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jnci\/dji055","volume":"97","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu H, Lin L, Takahashi T, et al. Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. JNCI J Natl Cancer Inst. 2005;97(5):339\u201346. \n                    https:\/\/doi.org\/10.1093\/jnci\/dji055\n                    \n                  .","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"11","key":"2075_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1590\/1414-431X20144099","volume":"47","author":"SEDC Jorge","year":"2014","unstructured":"Jorge SEDC, Kobayashi SS, Costa DB. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res. 2014;47(11):929\u201339. \n                    https:\/\/doi.org\/10.1590\/1414-431X20144099\n                    \n                  .","journal-title":"Braz J Med Biol Res"},{"issue":"5676","key":"2075_CR10","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497\u2013500. \n                    https:\/\/doi.org\/10.1126\/science.1099314\n                    \n                  .","journal-title":"Science."},{"issue":"3","key":"2075_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169\u201381. \n                    https:\/\/doi.org\/10.1038\/nrc2088\n                    \n                  .","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2075_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR Mutation and Resistance of Non\u2013Small-Cell Lung Cancer to Gefitinib. N Engl J Med. 2005;352(8):786\u201392. \n                    https:\/\/doi.org\/10.1056\/NEJMoa044238\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"8","key":"2075_CR13","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240\u20137. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2246\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2075_CR14","doi-asserted-by":"publisher","first-page":"e000060","DOI":"10.1136\/esmoopen-2016-000060","volume":"1","author":"F Morgillo","year":"2016","unstructured":"Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1(3):e000060. \n                    https:\/\/doi.org\/10.1136\/esmoopen-2016-000060\n                    \n                  .","journal-title":"ESMO Open"},{"issue":"6","key":"2075_CR15","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0709662105","volume":"105","author":"C-H Yun","year":"2008","unstructured":"Yun C-H, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci. 2008;105(6):2070\u20135. \n                    https:\/\/doi.org\/10.1073\/pnas.0709662105\n                    \n                  .","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"2075_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/annonc\/mdt573","volume":"25","author":"HA Yu","year":"2014","unstructured":"Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol. 2014;25(2):423\u20138. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdt573\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"4","key":"2075_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2011.38.3224","volume":"30","author":"KY Su","year":"2012","unstructured":"Su KY, Chen HY, Li KC, et al. Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30(4):433\u201340. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.38.3224\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"5","key":"2075_CR18","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1158\/1078-0432.CCR-10-2158","volume":"17","author":"R Rosell","year":"2011","unstructured":"Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations. Clin Cancer Res. 2011;17(5):1160\u20138. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2158\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2075_CR19","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1097\/JTO.0b013e3182653d7f","volume":"7","author":"Y Fujita","year":"2012","unstructured":"Fujita Y, Suda K, Kimura H, et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol. 2012;7(11):1640\u20134. \n                    https:\/\/doi.org\/10.1097\/JTO.0b013e3182653d7f\n                    \n                  .","journal-title":"J Thorac Oncol"},{"key":"2075_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/385087","volume":"2013","author":"Cristin Roma","year":"2013","unstructured":"Roma C, Esposito C, Rachiglio AM, et al. Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. Biomed Res Int. 2013;2013 \n                    https:\/\/doi.org\/10.1155\/2013\/385087\n                    \n                  .","journal-title":"BioMed Research International"},{"issue":"7","key":"2075_CR21","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jtho.2017.04.003","volume":"12","author":"Suzanne Jenkins","year":"2017","unstructured":"Jenkins S, Yang JC, Ramalingam SS, et al. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced non-small Cell Lung Cancer. J Thorac Oncol. 2017; \n                    https:\/\/doi.org\/10.1016\/j.jtho.2017.04.003\n                    \n                  .","journal-title":"Journal of Thoracic Oncology"},{"issue":"8","key":"2075_CR22","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.21037\/jtd.2017.07.02","volume":"9","author":"T Tatematsu","year":"2017","unstructured":"Tatematsu T, Okuda K, Suzuki A, et al. The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR. J Thorac Dis. 2017;9(8):2397\u2013403. \n                    https:\/\/doi.org\/10.21037\/jtd.2017.07.02\n                    \n                  .","journal-title":"J Thorac Dis"},{"issue":"11","key":"2075_CR23","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","volume":"17","author":"J-Y Wu","year":"2011","unstructured":"Wu J-Y, Yu C-J, Chang Y-C, Yang C-H, Shih J-Y, Yang P-C. Effectiveness of tyrosine kinase inhibitors on \u201cuncommon\u201d epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011;17(11):3812\u201321. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3408\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2075_CR24","doi-asserted-by":"publisher","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","volume":"64","author":"T Kosaka","year":"2004","unstructured":"Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res. 2004;64(24):8919\u201323. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-2818\n                    \n                  .","journal-title":"Cancer Res"},{"issue":"1","key":"2075_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3892\/or.2014.3197","volume":"32","author":"S Hashida","year":"2014","unstructured":"Hashida S, Soh J, Toyooka S, et al. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients. Oncol Rep. 2014;32(1):145\u201352. \n                    https:\/\/doi.org\/10.3892\/or.2014.3197\n                    \n                  .","journal-title":"Oncol Rep"},{"key":"2075_CR26","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.prp.2018.05.016","volume":"214","author":"S Sakashita","year":"2018","unstructured":"Sakashita S, Shiba-Ishii A, Murata Y, Sekimoto R, Minami Y, Sato Y, et al. Case report of three EGFR TKI na\u00efve lung adenocarcinoma containing double EGFR mutations (L858R\/T790M or Exon 19 Deletion\/T790M); Comparing genetic information and histology. Pathol Res Pract. 2018;214:1224\u201330.","journal-title":"Pathol Res Pract"},{"key":"2075_CR27","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.cllc.2015.11.003","volume":"17","author":"Y Lou","year":"2016","unstructured":"Lou Y, Pecot CV, Tran HT, DeVito VJ, Tang XM, Heymach JV, et al. Germline Mutation of T790M and Dual\/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clin Lung Cancer. 2016;17:e5\u201311.","journal-title":"Clin Lung Cancer."},{"issue":"7","key":"2075_CR28","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/j.jtho.2016.03.017","volume":"11","author":"J Khan","year":"2016","unstructured":"Khan J, Pritchard CC, Martins RG. Tissue Is the Issue for Diagnosis of EGFR T790M Mutation. J Thorac Oncol. 2016;11(7):e91\u20132.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2075_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-018-0270-7","volume":"38","author":"X Yu","year":"2018","unstructured":"Yu X, Zhang X, Zhang Z, Lin Y, Wen Y, Chen Y, et al. First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: A single institution\u2019s clinical practice experience. Cancer Commun. 2018;38(1):1\u201313.","journal-title":"Cancer Commun"},{"issue":"57","key":"2075_CR30","doi-asserted-by":"publisher","first-page":"96684","DOI":"10.18632\/oncotarget.18042","volume":"8","author":"PB Illei","year":"2017","unstructured":"Illei PB, Belchis D, Tseng L-H, Nguyen D, De Marchi F, Haley L, et al. Clinical mutational profiling of 1006 lung cancers by next generation sequencing. Oncotarget. 2017;8(57):96684\u201396.","journal-title":"Oncotarget."},{"issue":"6","key":"2075_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4274\/balkanmedj.2017.0297","volume":"34","author":"GG Tezel","year":"2017","unstructured":"Tezel GG, \u015eener E, Ayd\u0131n \u00c7, \u00d6nder S. Prevalence of epidermal growth factor receptor mutations in patients with non-small cell lung cancer in Turkish population. Balkan Med J. 2017;34(6):567\u201371.","journal-title":"Balkan Med J"},{"issue":"November","key":"2075_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.lungcan.2017.11.005","volume":"114","author":"H-Y Tu","year":"2017","unstructured":"Tu H-Y, Ke E-E, Yang J-J, et al. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer. 2017;114(November):96\u2013102. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2017.11.005\n                    \n                  .","journal-title":"Lung Cancer"},{"issue":"8","key":"2075_CR33","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/14737159.2016.1199961","volume":"16","author":"Y Tang","year":"2016","unstructured":"Tang Y, Wang WY, Zheng K, Jiang L, Zou Y, Su XY, et al. EGFR mutations in non-small cell lung cancer: an audit from West China Hospital. Expert Rev Mol Diagn. 2016;16(8):915\u20139.","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"2075_CR34","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.cllc.2017.07.002","volume":"19","author":"Takahisa Kawamura","year":"2018","unstructured":"Kawamura T, Kenmotsu H, Omori S, et al. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer. Clin Lung Cancer. 2017; \n                    https:\/\/doi.org\/10.1016\/j.cllc.2017.07.002\n                    \n                  .","journal-title":"Clinical Lung Cancer"},{"issue":"1","key":"2075_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cllc.2014.09.002","volume":"16","author":"Y Lee","year":"2015","unstructured":"Lee Y, Lee GK, Hwang JA, Yun T, Kim HT, Lee JS. Clinical likelihood of sporadic primary EGFR T790M Mutation in EGFR-mutant Lung Cancer. Clin Lung Cancer. 2015;16(1):46\u201350. \n                    https:\/\/doi.org\/10.1016\/j.cllc.2014.09.002\n                    \n                  .","journal-title":"Clin Lung Cancer"},{"issue":"21","key":"2075_CR36","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","volume":"29","author":"M Fukuoka","year":"2011","unstructured":"Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866\u201374. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.33.4235\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"16","key":"2075_CR37","doi-asserted-by":"publisher","first-page":"7854","DOI":"10.1158\/0008-5472.CAN-06-1951","volume":"66","author":"M Inukai","year":"2006","unstructured":"Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006;66(16):7854\u20138. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1951\n                    \n                  .","journal-title":"Cancer Res"},{"key":"2075_CR38","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2217\/fon-2018-0626","volume":"15","author":"J Carlisle","year":"2019","unstructured":"Carlisle J, Ramalingam S. Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future Oncol. 2019;15:805\u201316.","journal-title":"Future Oncol"},{"issue":"9","key":"2075_CR39","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046\u201361.","journal-title":"Cancer Discov"},{"issue":"18","key":"2075_CR40","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA Janne","year":"2015","unstructured":"Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689\u201399.","journal-title":"N Engl J Med"},{"issue":"12","key":"2075_CR41","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","volume":"35","author":"JC Yang","year":"2017","unstructured":"Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study Phase II extension component. J Clin Oncol. 2017;35(12):1288\u201396.","journal-title":"J Clin Oncol"},{"key":"2075_CR42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"T Mok","year":"2017","unstructured":"Mok T, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam S, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376:629\u201340.","journal-title":"N Engl J Med"},{"issue":"2","key":"2075_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"key":"2075_CR44","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/cncr.31891","volume":"125","author":"MY Ahn","year":"2019","unstructured":"Ahn MY, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T. Osimertinib in Patients With T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up From a Pooled Analysis of 2 Phase 2 Studies. Cancer. 2019;125:892\u2013901.","journal-title":"Cancer."},{"key":"2075_CR45","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1158\/1078-0432.CCR-18-3325","volume":"25","author":"D Planchard","year":"2019","unstructured":"Planchard D, Boyer MJ, Lee JS, Dechaphunkul A, Cheema PK, Takahashi T. Post-Progression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-3 Mutated Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2019;25:2058\u201363.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2075_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CCO.0000000000000495","volume":"31","author":"J Roeper","year":"2019","unstructured":"Roeper J, Griesinger F. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer: what is the preferred first-line therapy? Curr Opin Oncol. 2019;31(1):1\u20137.","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"2075_CR47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40267-018-0536-9","volume":"34","author":"LJ Scott","year":"2018","unstructured":"Scott LJ. Osimertinib as first-line therapy in advanced NSCLC: a profile of its use. Drugs Ther Perspect. 2018;34(8):351\u20137.","journal-title":"Drugs Ther Perspect"},{"issue":"1","key":"2075_CR48","first-page":"27","volume":"117","author":"B Zhang","year":"2018","unstructured":"Zhang B, Xu JL, Zhang X, Gu P, Wang HM, Wang SY. Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)? Lung Cancer. 2018;117(1):27\u201331.","journal-title":"Lung Cancer"},{"issue":"1","key":"2075_CR49","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/annonc\/mdt573","volume":"25","author":"HA Yu","year":"2014","unstructured":"Yu HA, Arcila ME, Hellmann MD, et al. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol. 2014;25(1):423\u20138.","journal-title":"Ann Oncol"},{"issue":"7","key":"2075_CR50","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","volume":"16","author":"JC Yang","year":"2015","unstructured":"Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830\u20138.","journal-title":"Lancet Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-019-2075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-019-2075-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-019-2075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T23:20:27Z","timestamp":1589412027000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-019-2075-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2075"],"URL":"https:\/\/doi.org\/10.1186\/s13256-019-2075-y","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2019,5,15]]},"assertion":[{"value":"3 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"144"}}